Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Clinical trial NCT06343376 · TERMINATED

Trial details

NCT number: NCT06343376
Sponsor: Roswell Park Cancer Institute
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent High Grade B-Cell Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Transformed Chronic Lymphocytic Leukemia Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory High Grade B-Cell Lymphoma Refractory Mantle Cell Lymphoma

Start date: 2024-11-26
Primary completion: 2025-01-03
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.